J Korean Endocr Soc.  2010 Mar;25(1):25-27. 10.3803/jkes.2010.25.1.25.

Comparison of the Efficacy of Octreotide Long-acting Repeatable and Lanreotide Autogel in Acromegalic Patients

• Park JK
• Lee EJ

• KMID: 2177857
• DOI: http://doi.org/10.3803/jkes.2010.25.1.25

Abstract

No abstract available.

MeSH Terms

Humans
Octreotide
Peptides, Cyclic
Somatostatin
Octreotide
Peptides, Cyclic
Somatostatin

Reference

1. Roelfsema F, Biermasz NR, Pereira AM, Romijn JA. Therapeutic options in the management of acromegaly: focus on lanreotide Autogel. Biologics. 2008. 2:463–479.

2. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004. 89:1613–1617.

3. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004. 89:667–674.

4. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998. 83:2730–2734.

5. Melmed S. Medical progress: acromegaly. N Engl J Med. 2006. 355:2558–2573.

6. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008. 93:2957–2968.

7. Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol. 1999. 141:267–271.

8. Turner HE, Vadivale A, Keenan J, Wass JA. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf). 1999. 51:275–280.

9. van Thiel SW, Romijn JA, Biermasz NR, Ballieux BE, Frölich M, Smit JW, Corssmit EP, Roelfsema F, Pereira AM. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol. 2004. 150:489–495.

10. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf). 2008. 68:473–480.

11. Ashwell SG, Bevan JS, Edwards OM, Harris MM, Holmes C, Middleton MA, James RA. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol. 2004. 150:473–480.

12. Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, Maiter D. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004. 151:317–324.

13. McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs. 2003. 63:2473–2499.

14. Feelders RA, Hofland LJ, van Aken MO, Neggers SJ, Lamberts SW, de Herder WW, van der Lely AJ. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs. 2009. 69:2207–2226.